Individual Study / EPHESUS

Eplerenone Post Acute Myocardial Infarction Heart Failure Efficacy and Survival Study

Eplerenone Post Acute Myocardial Infarction Heart Failure Efficacy and Survival Study

Initiatives -
Aldosterone blockade reduces mortality and morbidity among patients with severe heart failure. We conducted a double-blind, placebo-controlled study evaluating the effect of eplerenone, a selective aldosterone blocker, on morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure. *Note: All published information has been collected from the article referenced in the Marker Paper box below. Therefore, there may be variations with more advanced versions of the study.*

Members

Download
Investigators Contacts
  • Dr. Prof. Bertram Pitt
    University of Michigan Medical Center

Design

Study design
Clinical trial cohort
Follow Up
mean follow-up of 16 months

Marker Paper

Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003 Apr 3;348(14):1309-21. doi: 10.1056/NEJMoa030207. Epub 2003 Mar 31. Erratum in: N Engl J Med. 2003 May 29;348(22):2271.

PUBMED 12668699

Recruitment

Sources of Recruitment
  • Individuals

Number of participants

Number of participants
6,632
Number of participants with biosamples

Access

Availability of data and biosamples

Data
Biosamples
Other